Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007, Article ID 90289, 10 pages
Review Article

Peroxisome Proliferator-Activated Receptors in Lung Cancer

1Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI 48109, USA
2Division of Pulmonary, Allergy and Critical Care Medicine, Emory University, School of Medicine, Atlanta, GA 30322, USA
3Atlanta Veterans Affairs Medical Center, Atlanta, GA 30033, USA

Received 11 April 2007; Accepted 3 July 2007

Academic Editor: T. J. Standiford

Copyright © 2007 Venkateshwar G. Keshamouni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily. Their discovery in the 1990s provided insights into the cellular mechanisms involved in the control of energy homeostasis; the regulation of cell differentiation, proliferation, and apoptosis; and the modulation of important biological and pathological processes related to inflammation, among others. Since then, PPARs have become an exciting therapeutic target for several diseases. PPARs are expressed by many tumors including lung carcinoma cells, and their function has been linked to the process of carcinogenesis in lung. Consequently, intense research is being conducted in this area with the hope of discovering new PPAR-related therapeutic targets for the treatment of lung cancer. This review summarizes the research being conducted in this area and focuses on the mechanisms by which PPARs are believed to affect lung tumor cell biology.